## PATENT COOPERATION TREATY

INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) 18.06.2004 24.06.2003 PCT/US2004/019420 International Patent Classification (IPC) or both national classification and IPC A61K31/133, A61P9/00 Applicant UNIVERSITY OF CONNECTICUT This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application **FURTHER ACTION** 2. If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Due: Name and mailing address of the ISA: Authorized Officer European Patent Office Cattell, James D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d

Telephone No. +49 89 2399-8468

Fax: +49 89 2399 - 4465

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/019420

_	Box N	o. I Basis of the opinion	
		egard to the language, this opinion has been established on the basis of the international application in guage in which it was filed, unless otherwise indicated under this item.	
	la	nis opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).	
<b>2</b> .	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:		
	a. type	of material:	
	-🗆	a sequence listing	
		table(s) related to the sequence listing	
	b. form	at of material:	
		in written format	
		in computer readable form	
	c. time	of filing/furnishing:	
		contained in the international application as filed.	
	. 🗀	filed together with the international application in computer readable form.	
		furnished subsequently to this Authority for the purposes of search.	
3.	ha co	addition, in the case that more than one version or copy of a sequence listing and/or table relating theretos been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.	
4.	4. Additional comments:		

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-21

No: Claims

Inventive step (IS)

Yes: Claims

1-21

No: Claims

Industrial applicability (IA)

Yes: Claims

1-21

No: Claims

2. Citations and explanations

see separate sheet

## Box No. VI Certain documents cited

 Certain published documents (Rules 43bis.1 and 70.10) and / or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/US2004/019420

- The documents cited in the search report are to be regarded as being numbered D1-D2 in their order of citation. The IPEA intend to refer to the sections of these documents highlighted in the search report, unless otherwise specified.
- D2 discloses the first medical use of FTY720 an immunosuppressant.
  The use to treat vascular permeability disorders is not disclosed or obvious from D2.